|
|
Predictive Value of Serum LDH and its Isoenzymes, FAR for Prognosis of Patients with Acute Exacerbation of COPD |
SU Hui, DONG Pengfei, XU Pei, et al |
Department of Laboratory Medicine, the First Affiliated Hospital of Henan University of Science and Technology, Luoyang Henan 471000 |
|
|
Abstract 【Objective】To explore the predictive value of serum lactate dehydrogenase (LDH) and its isoenzymes, fibrinogen (FIB)/albumin (ALB) ratio (FAR) for the prognosis of patients with acute exacerbation of chronic obstructive pulmonary disease (COPD). 【Methods】 The clinical data of 81 patients with acute exacerbation of COPD treated in our hospital from January 2022 to June 2024 were retrospectively analyzed. According to the prognosis within 1 year after treatment, the patients were divided into poor prognosis group (n=32) and good prognosis group (n=49). The general data, serum LDH and its isoenzymes, and FAR were compared between the two groups. Logistic multivariate regression was used to analyze the risk factors for poor prognosis in patients with acute exacerbation of COPD, and receiver operating characteristic (ROC) curve was used to analyze the predictive value of serum LDH and its isoenzymes, FAR for the prognosis of such patients. 【Results】The FAR and serum LDH1, LDH2, LDH4, LDH5, total LDH levels in the poor prognosis group were higher than those in the good prognosis group, with statistically significant differences (P<0.05). High levels of FAR, serum LDH1, LDH4, LDH5, and total LDH were risk factors for poor prognosis in patients with acute exacerbation of COPD (P<0.05). ROC curve analysis showed that FAR, serum LDH1, LDH4, LDH5, and total LDH levels all had certain predictive value for the prognosis of patients with acute exacerbation of COPD, and the combined prediction value of these indicators was better than that of single indicator. 【Conclusion】Serum LDH and its isoenzymes, FAR have certain predictive value for the prognosis of patients with acute exacerbation of COPD, and the combined detection of these indicators has a better predictive value than single indicator.
|
Received: 18 May 2025
|
|
|
|
|
[1] 刘爱丽,段福明,冯伟. 慢性阻塞性肺疾病患者血清TLR4、HDAC2水平与气道炎症反应及免疫功能的关系[J].医学临床研究,2025,42(3):504-506.
[2] 杨建华. 血清sCD14联合sCD30对老年慢性阻塞性肺疾病合并肺部真菌感染的诊断价值[J].医学临床研究,2025,42(2):225-227.
[3] 毕周奎,徐瑜,郭亮,等. 外周血炎症指标对晚期非小细胞肺癌合并慢性阻塞性肺疾病患者免疫治疗疗效的影响[J].中华医学杂志,2024,104(18):1601-1609.
[4] 南黎,王华,葛廷. 纤维蛋白原与白蛋白比值对慢阻肺急性加重风险的预测价值分析[J].实用中西医结合临床,2022,22(11):76-79.
[5] 中华医学会呼吸病学分会慢性阻塞性肺疾病学组,中国医师协会呼吸医师分会慢性阻塞性肺疾病工作委员会. 慢性阻塞性肺疾病诊治指南(2021年修订版)[J].中华结核和呼吸杂志,2021,44(3):170-205.
[6] 尹力,张东亚,蒋波. 缩唇-腹式呼吸联合高频胸壁振荡排痰对慢阻肺急性加重期患者的影响研究[J].护士进修杂志,2023,38(12):1128-1130.
[7] 彭丽阁,刘师漫,蒲佳琪,等. 慢性阻塞性肺疾病合并肺栓塞院内不良结局相关因素及sPESI评分对其预测价值[J].中华医学杂志,2024,104(42):3889-3895.
[8] 鞠丹丹,黄隽敏,李淑娇,等. 急性心肌梗死合并肺部感染病原菌分布及高敏肌钙蛋白、肌酸激酶同工酶与乳酸脱氢酶水平变化与炎性因子的关系[J].实用医院临床杂志,2022,19(3):137-140.
[9] 刘晓曼,陈旭,张新征. 重症肺炎患者C-反应蛋白、磷酸肌酸激酶同工酶及乳酸脱氢酶水平变化及临床意义[J].实用医院临床杂志,2022,19(3):174-177.
[10] 赵静,杨婷,杜小琴,等. 纤维蛋白原与白蛋白比值对慢阻肺患者急性加重风险的预测价值分析[J].首都食品与医药,2022,29(11):26-28.
[11] 黄琴,蒿艳蓉,吕艳茹,等. 系统免疫炎症指数、纤维蛋白原与白蛋白比值对晚期肺癌一线化疗患者预后的影响[J].广西医科大学学报,2023,40(8):1321-1328. |
|
|
|